Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Final Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial

被引：10
|
作者：
Jerkeman, Mats
Hutchings, Martin
Raty, Riikka
Wader, Karin Fahl
Laurell, Anna
Christensen, Jacob H.
Kuitunen, Hanne
Eskelund, Christian Winther
Groenbaek, Kirsten
Niemann, Carsten Utoft
Geisler, Christian H.
Kolstad, Arne
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-133298
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: First Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial
    Jerkeman, Mats
    Hutchings, Martin
    Raty, Riikka
    Wader, Karin Fahl
    Laurell, Anna
    Kuitunen, Hanne
    Toldbod, Helle
    Pedersen, Lone Bredo
    Eskelund, Christian Winther
    Gronbaek, Kirsten
    Niemann, Carsten Utoft
    Geisler, Christian H.
    Kolstad, Arne
    BLOOD, 2016, 128 (22)
  • [2] Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long-term follow-up of the Nordic Lymphoma Group MCL6 Philemon trial
    Forsgren, Elin
    Jorgensen, Rasmus R. K.
    Bentzen, Hans
    Riise, Jon
    Haaber, Jacob
    Pasanen, Annika
    Kuitunen, Hanne
    Wader, Karin F.
    El-Galaly, Tarec C.
    Hutchings, Martin
    Glimelius, Ingrid
    Jerkeman, Mats
    HEMASPHERE, 2025, 9 (03):
  • [3] Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase Ib-II Trial
    Jerkeman, Mats
    Kolstad, Arne
    Hutchings, Martin
    Pasanen, Annika
    Meriranta, Leo
    Niemann, Carsten Utoft
    Jorgensen, Rasmus Rask Kragh
    El-Galaly, Tarec Christoffer Christoffer
    Riise, Jon
    Leppa, Sirpa
    Christensen, Jacob Haaber
    Wader, Karin Fahl
    Glimelius, Ingrid
    BLOOD, 2022, 140
  • [4] Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial
    S Ferrero
    A Pastore
    C W Scholz
    R Forstpointner
    A Pezzutto
    L Bergmann
    L Trümper
    J Finke
    U Keller
    P Ghione
    R Passera
    W Hiddemann
    O Weigert
    M Unterhalt
    M Dreyling
    Leukemia, 2016, 30 : 984 - 987
  • [5] Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial
    Ferrero, S.
    Pastore, A.
    Scholz, C. W.
    Forstpointner, R.
    Pezzutto, A.
    Bergmann, L.
    Truemper, L.
    Finke, J.
    Keller, U.
    Ghione, P.
    Passera, R.
    Hiddemann, W.
    Weigert, O.
    Unterhalt, M.
    Dreyling, M.
    LEUKEMIA, 2016, 30 (04) : 984 - 987
  • [6] Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial
    Jerkeman, Mats
    Eskelund, Christian Winther
    Hutchings, Martin
    Raty, Riikka
    Wader, Karin Fahl
    Laurell, Anna
    Toldbod, Helle
    Pedersen, Lone Bredo
    Niemann, Carsten Utoft
    Dahl, Christina
    Kuitunen, Hanne
    Geisler, Christian H.
    Gronbaek, Kirsten
    Kolstad, Arne
    LANCET HAEMATOLOGY, 2018, 5 (03): : E109 - E116
  • [7] A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501).
    Morrison, V. A.
    Jung, S.
    Johnson, J. L.
    Leonard, J.
    Cheson, B. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - Data from the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase I Trial: Stopping Treatment in Molecular Remission Is Feasible
    Jerkeman, Mats
    Kolstad, Arne
    Niemann, Carsten Utoft
    Groenbaek, Kirsten
    Hutchings, Martin
    Pasanen, Annika
    Ekberg, Sara
    Wader, Karin Fahl
    Glimelius, Ingrid
    BLOOD, 2020, 136
  • [9] Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma
    Garbo, Lawrence E.
    Flynn, Patrick J.
    MacRae, Margaret A.
    Rauch, Mary A.
    Wang, Yunfei
    Kolibaba, Kathryn S.
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (05) : 476 - 481
  • [10] Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma
    Lawrence E. Garbo
    Patrick J. Flynn
    Margaret A. MacRae
    Mary A. Rauch
    Yunfei Wang
    Kathryn S. Kolibaba
    Investigational New Drugs, 2009, 27 : 476 - 481
12345